Latest News

Tirzepatide Proves Noninferiority with Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off / image credit ©MichaelVI/stock.adobe.com
Tirzepatide Proves Noninferiority with Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off

August 1st 2025

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data
FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

July 14th 2025

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns
GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

July 9th 2025

BF% outperforms BMI in Predicting Morality risk in young adults: New Findings / image courtesy of University of Florida
Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

July 8th 2025

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data
Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

June 23rd 2025

More News

© 2025 MJH Life Sciences

All rights reserved.